CNBX Pharmaceuticals, Inc. (CNBX)
0.0001
0.00 (0.00%)
USD |
OTCM |
Sep 17, 16:00
CNBX Pharmaceuticals Free Cash Flow : -0.1542M for May 31, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| May 31, 2026 | -0.1542M |
| February 28, 2026 | -0.1585M |
| November 30, 2025 | -0.1796M |
| August 31, 2025 | -0.1713M |
| May 31, 2025 | -0.191M |
| February 28, 2025 | -0.1388M |
| November 30, 2024 | -0.2115M |
| August 31, 2024 | -0.2455M |
| May 31, 2024 | -0.1767M |
| February 29, 2024 | -0.1955M |
| November 30, 2023 | -0.0897M |
| August 31, 2023 | -0.1125M |
| May 31, 2023 | -0.2836M |
| February 28, 2023 | -0.6404M |
| November 30, 2022 | -1.177M |
| August 31, 2022 | -1.681M |
| May 31, 2022 | -2.112M |
| February 28, 2022 | -2.353M |
| November 30, 2021 | -2.500M |
| August 31, 2021 | -2.494M |
| May 31, 2021 | -2.626M |
| February 28, 2021 | -2.646M |
| November 30, 2020 | -2.673M |
| August 31, 2020 | -2.851M |
| May 31, 2020 | -3.036M |
| Date | Value |
|---|---|
| February 29, 2020 | -3.288M |
| November 30, 2019 | -3.339M |
| August 31, 2019 | -3.311M |
| May 31, 2019 | -3.233M |
| February 28, 2019 | -2.909M |
| November 30, 2018 | -3.203M |
| August 31, 2018 | -2.917M |
| May 31, 2018 | -2.474M |
| February 28, 2018 | -2.204M |
| November 30, 2017 | -1.300M |
| August 31, 2017 | -0.9894M |
| May 31, 2017 | -0.6806M |
| February 28, 2017 | -0.3746M |
| November 30, 2016 | -0.2314M |
| August 31, 2016 | -0.1201M |
| May 31, 2016 | -0.078M |
| February 29, 2016 | -0.0735M |
| November 30, 2015 | -0.1044M |
| August 31, 2015 | -0.1821M |
| May 31, 2015 | |
| February 28, 2015 | |
| November 30, 2014 | |
| May 31, 2014 | -0.1655M |
| February 28, 2014 | -0.1091M |
| November 30, 2013 | -0.0686M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Cocrystal Pharma, Inc. | -8.276M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -208.80M |
| Fulcrum Therapeutics, Inc. | -66.14M |
| Definium Therapeutics, Inc. | -166.74M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -0.0477M |
| Cash from Financing (Quarterly) | 0.045M |
| Free Cash Flow to Equity (Quarterly) | -0.0495M |
| Free Cash Flow to Firm (Quarterly) | -0.0477M |
| Free Cash Flow Yield | -174.4% |